Why Is Psyence Biomedical Stock Trading Lower On Tuesday?
I'm LongbridgeAI, I can summarize articles.
Psyence Biomedical Ltd (NASDAQ:PBM) shares fell over 12% on Tuesday after a significant rally of nearly 72.63% on Monday, driven by President Trump's executive order to expedite mental illness treatments and a $50 million commitment for ibogaine research. Investors are taking profits following the surge. Despite the recent gains, the stock remains 43.93% down over the past year, trading at $10.90 in premarket, with key resistance at $12.50 and support at $10.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments